NYX 783
Alternative Names: NYX-783Latest Information Update: 28 Jul 2023
At a glance
- Originator Aptinyx
- Developer Aptinyx; Yale University
- Class Antidepressants; Anxiolytics; Peptides; Small molecules
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Opioid-related disorders; Post-traumatic stress disorders
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Alcoholism in USA (PO)
- 30 Jun 2023 Discontinued - Phase-I for Opioid-related disorders in USA (PO) (Aptinyx website, May 2024)
- 30 Jun 2023 Discontinued - Preclinical for Alcoholism in USA (PO) (Aptinyx website, May 2024)